Pirenzepine topical - WinSanTor

Drug Profile

Pirenzepine topical - WinSanTor

Alternative Names: Topical pirenzepine - WinSanTor; WST 057; WST-1; WST01; WST1/analgesic; WST57

Latest Information Update: 29 Jun 2017

Price : $50

At a glance

  • Originator University of California, San Diego; University of Manitoba
  • Developer WinSanTor
  • Class Antidementias; Antiulcers; Benzodiazepinones; Gastric antisecretories; Small molecules
  • Mechanism of Action Muscarinic M1 receptor antagonists; Sensory receptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Diabetic neuropathies
  • Research Neuropathic pain

Most Recent Events

  • 26 Apr 2017 WinSanTor plans a phase I trial in Healthy volunteers in Australia (ACTRN12617000535370p)
  • 17 Jan 2017 WinSanTor plans a proof-of-concept phase II trial for diabetic peripheral chemo-induced neuropathies in Europe, Canada and China (WinSanTor pipeline, June 2017)
  • 17 Jan 2017 Phase-I clinical trials in Diabetic neuropathies (In volunteers) in Australia (Topical) before January 2017 (ACTRN12617000535370p) (WinSanTor pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top